Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led to greater rates of MASH resolution, an interim analysis of a phase III ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback